\n\u201cIn the first quarter of 2023, we made excellent progress advancing Equillium\u2019s wholly-owned multi-cytokine inhibitors, EQ101 and EQ102, in their respective clinical programs in alopecia areata and first-in-human development, as well as continuing to advance our pivotal Phase 3 EQUATOR study in aGVHD and Phase 1b EQUALISE study in lupus nephritis,\u201d said Bruce Steel, chief executive officer at Equillium. \u201cWith the Ono Pharmaceutical partnership now in place, and Equillium in a strong financial position, our team is focused on achieving near-term milestones in the multi-cytokine programs before the end of the year, including initial data from the EQ101 Phase 2 study in alopecia areata. While we believe the multi-cytokine programs represent a significant source of long-term value, we remain highly engaged in the ongoing development of itolizumab and plan to report topline data from the EQUALISE study in lupus nephritis in the first half of 2024 and remain currently on track for the interim review of the Phase 3 EQUATOR study later in 2024. We look forward to these two milestones as they will establish Ono\u2019s option exercise timeline for itolizumab, which if exercised would result in a payment of approximately $371<\/sup> million and significantly extend Equillium\u2019s cash runway.\u201d<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230511005715\/en\/1791374\/3\/1_Equillium_Logo_400x400.jpg\"){kind=logo}
<\/td>\n<\/tr>\n